ARAZLO (nda211882)- (0.045%)

Generic Name	TAZAROTENE	Innovator	BAUSCH
Dosage	0.045%
ParaIV Filing	Yes	505(b)2 Filing	Yes
Last Patent Expiry	2038-May-11	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	2022-Dec-18
GAIN Expiry	None	Drug Complexity	No
Indication	ARAZLO is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	3

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
0.045%	**	**	Up	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	0

Manufacturing Details of ARAZLO